Batavia Biosciences focuses on accelerating the transition of biopharmaceutical product candidates from discovery to the clinic with improved success and lower cost. We are your flexible partner to rely on at all stages of biopharmaceutical process development.

To accelerate the journey to the clinic, we offer a full range of development and manufacturing services for all major classes of biopharmaceutical, and have developed a portfolio of technologies aimed to improve product yield, reduce process development time and increase product stability. These technologies have demonstrated to reduce risks, improve timelines and reduce costs in biopharmaceutical development to make sure the product receives the patient without any unnecessary delays. We are an active player in Global Health, where we collaborate with prominent academic institutions and public organizations to improve the availability and affordability of key biopharmaceuticals for all in need.

Equipped to tackle challenges

The company employs a highly educated staff with many years of experience in DNA cloning, mammalian cell line generation, upstream process development, purification development, product characterization, and clinical manufacturing. As such the company, with laboratories in USA and the Netherlands, is well positioned to take on any challenge associated with the development of complex biological medicines be it proteins, antibodies, vaccines or viral vectors.

Batavia Biosciences

03/09/2021

Expansion viral vector capacity in Boston area

Expansion of the R&D facility in Woburn, (MA) allows us to expand process development capacity for HIP-Vax. Through innovative bioprocess intensification, HIP-Vax technology allows clinical manufacturing at a lab-scale.

02/12/2019

10-year anniversary

We are celebrating! Ten years ago, Chris Yallop and Menzo Havenga incorporated Batavia Biosciences at the chamber of commerce in the Netherlands. The company started operations on January 1, 2010 at that time with 7 employees.

16/10/2017

Expansion viral vector and GMP facilities

Announcement of the 4,000 ft2 expansion of the viral vector process development facilities in the USA and GMP clean room facilities in the Netherlands to accommodate the increasing market demand.

01/12/2016

100 employees

Batavia Biosciences hires its 100th employee! The company is proud to have a highly educated and very experienced staff.

14/12/2015

Moving to new facility NL

To accommodate the fast growth, Batavia Biosciences needed a new facility in the Netherlands. Therefore, a brand new, state of the art, office and laboratory infrastructure (65,000 ft2) was built just across the street of the old location at the Leiden BioScience Park.

23/04/2015

Bioservices becomes Biosciences

Batavia Bioservices changes its name to Batavia Biosciences. The new name better reflects the added value and scientific support that we bring to our sponsors as well as our R&D staff’s efforts in developing exciting novel technologies to accelerate biopharmaceutical product development.

24/10/2014

Opening sales office Hong Kong

In 2014 the company opened an office in Hong Kong to serve the growing order portfolio in Asia.

03/04/2012

Launch of US subsidiary

Batavia Bioservices Inc. launches laboratory infrastructure in the Greater Boston area. 10,000 ft2 of dedicated BSL-2 laboratories are fully equipped to accommodate the increasing market demand from the US.

25/08/2011

Acquisition of Xendo Manufacturing B.V.

The acquisition gave Batavia access to simulated moving bed purification technology as well as infrastructure, and microbial process and product development. With the acquisition the company had doubled its staff.

01/01/2010

The company was founded

Menzo Havenga and Chris Yallop founded, what was then still called, Batavia Bioservices. With a staff of 7 dedicated people, vaccine and therapeutic protein projects for the first customers were executed.